Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalem... Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Show more
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower...
XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 9.62343096234 | 2.39 | 2.64 | 2.33 | 1019347 | 2.48175442 | CS |
4 | 0.38 | 16.9642857143 | 2.24 | 2.64 | 2.03 | 1141121 | 2.35115567 | CS |
12 | 0.72 | 37.8947368421 | 1.9 | 2.64 | 1.72 | 1326051 | 2.18666416 | CS |
26 | 0.16 | 6.50406504065 | 2.46 | 3.26 | 1.69 | 1599805 | 2.3586654 | CS |
52 | 0.21 | 8.71369294606 | 2.41 | 3.26 | 1.46 | 1517797 | 2.26828522 | CS |
156 | -0.71 | -21.3213213213 | 3.33 | 3.405 | 0.9701 | 1688212 | 2.24243597 | CS |
260 | -9.63 | -78.612244898 | 12.25 | 12.5039 | 0.9701 | 1701166 | 3.13322112 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.